Disease or Syndrome – Page 8

AI is Transforming Drug Safety—But Governance Sets Essential Guardrails

4 weeks ago talkbio0Tagged Adverse reaction to drug, AI guardrails, Artificial Intelligence, Bias (Epidemiology), Data Integrity, drug safety, Jeavons syndrome, patient safety, Pharmacovigilance, regulatory governance, United States Food and Drug Administration

artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety

Boehringer Ingelheim Breaks Decade-Long Drought with FDA Approval of Jascayd for Idiopathic Pulmonary Fibrosis

4 weeks ago talkbio0Tagged Approved, Boehringer Ingelheim, Chronic lung disease, Idiopathic Pulmonary Fibrosis, Jascayd, lung scarring, nerandomilast, Pulmonary Fibrosis, United States Food and Drug Administration

Boehringer Ingelheim; Jascayd; nerandomilast; FDA approval; idiopathic pulmonary fibrosis; IPF; lung scarring; first new treatment; chronic lung disease

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

4 weeks ago talkbio0Tagged Autoimmune Diseases, BTK inhibitor, Clinical Trials, Inhibitor, InnoCare, Interleukin-17, Multiple Sclerosis, orelabrtuinib, Pharma, TYK2 gene, Zenas BioPharma

Zenas BioPharma; InnoCare Pharma; autoimmune diseases; multiple sclerosis; BTK inhibitor; orelabrtuinib; licensing deal; clinical trials; IL-17 inhibitor; TYK2 inhibitor

CDC Updates COVID-19 and Chickenpox Vaccine Guidance Based on ACIP Recommendations

4 weeks ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), Chickenpox, Chickenpox Vaccine, COVID19 (disease), Febrile Convulsions, Immunization Schedule, individual-based decision-making, measles, mumps, rubella, varicella vaccine, Vaccines

CDC; COVID-19 vaccine; chickenpox vaccine; ACIP; individual-based decision-making; MMRV; varicella; immunization schedule; febrile seizure

NanoPhoria Secures €83.5M Series A for Heart Failure Therapy; AstraZeneca and Algen Ink Up to $555M AI Drug Discovery Pact

4 weeks ago talkbio0Tagged AI drug discovery, Algen Biotechnologies, AstraZeneca, Clustered Regularly Interspaced Short Palindromic Repeats, Deal Value, gene modulation, Heart failure, Immunology, nano-in-micro delivery, NanoPhoria, NP-MP1, Series A

NanoPhoria; Series A; heart failure; NP-MP1; nano-in-micro delivery; AstraZeneca; Algen Biotechnologies; AI drug discovery; immunology; CRISPR; gene modulation; deal value

Rocket Pharmaceuticals Withdraws FDA Application for Rare Blood Disease Gene Therapy

4 weeks ago talkbio0Tagged Fanconi Anemia, gene therapy, Mozafancogene Autotemcel, pipeline pivot, Rocket Pharmaceuticals, United States Food and Drug Administration

Rocket Pharmaceuticals; FDA; RP-L102; Fanconi Anemia; Gene Therapy; Pipeline Pivot

Legal Pressure Escalates as FDA Intensifies Crackdown on Direct-to-Consumer Pharma Advertising

1 month ago talkbio0Tagged Advertising (activity), CHARGE Syndrome, Compound, Direct-to-Consumer Advertising, enforcement, Legal Challenges, pharmaceutical advertising crackdown, Pharmacy facility, prescription drug ads, Preventive monitoring, United States Food and Drug Administration, warning letters

FDA enforcement; direct-to-consumer advertising; pharmaceutical advertising crackdown; warning letters; legal challenges; AI monitoring; prescription drug ads; transparency in advertising; HHS; compounding pharmacies

Transforming Patient Data into Therapeutic Breakthroughs in 2025

1 month ago talkbio0Tagged Diagnostics, Digital therapeutics, Precision Medicine

AI diagnostics; Digital therapeutics; Personalized medicine

Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data

1 month ago talkbio0Tagged amgen, Approved, Cardiovascular Diseases, Cardiovascular event, Cerebrovascular accident, LDL-C, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, United States Food and Drug Administration, VESALIUS-CV trial

Amgen; Repatha; VESALIUS-CV trial; primary prevention; cardiovascular disease; PCSK9 inhibitor; LDL-C; FDA approval; major adverse cardiovascular events; heart attack; stroke

Cirrus Therapeutics Raises $11M to Advance Gene Therapy Targeting Dry Age-Related Macular Degeneration

1 month ago talkbio0Tagged AAVS1 gene, Blindness, Cirrus, Dry AMD, gene therapy, IRAK3 gene, ocular immunology

Cirrus Therapeutics; gene therapy; dry AMD; IRAK-M; AAV; seed funding; ocular immunology; vision loss